AstraZeneca and Daiichi Sankyo’s breast cancer therapeutic Enhertu received supplemental approval from the U.S. Food and Drug Administration. Enhertu was approved for treating adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
Cosette Pharmaceuticals Inc., a New Jersey-based pharmaceutical company, announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).
As part of a restructuring of the company’s research and development areas, Tokyo-based Daiichi Sankyo announced the closing of the Plexxikon R&D subsidiary in South San Francisco.
Lung Cancer Breakthroughs Touted at ESMO 2021
AstraZeneca, Clinical Data, Clinical Trials, Daiichi Sankyo, EGFR tyrosine kinase inhibitors (TKI), European Society for Medical Oncology (ESMO), Janssen, KRAS Mutations, Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-Based Chemotherapy, R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics, Topline DataCompanies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.